



(11) Publication number: **0 453 301 A2**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: 91303516.8

(51) Int. Cl.⁵: **C12Q 1/68, G01N 33/50**

(22) Date of filing: 19.04.91

(30) Priority: 20.04.90 US 511651

(43) Date of publication of application:
23.10.91 Bulletin 91/43

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE


(71) Applicant: **SYNTEX (U.S.A.) INC.**
3401 Hillview Avenue
Palo Alto California 94304 (US)

(72) Inventor: **Ullman, Edwin F.**
135 Selby Lane
Atherton, California 94025 (US)
Inventor: **Goodman, Thomas C.**
2435 Whitney Drive
Mountain View, California 94043 (US)

(74) Representative: **Nicholls, Kathryn Margaret et al**
Mewburn Ellis, 2 Cursitor Street
London EC4A 1BQ (GB)

(54) **Double receptor polynucleotide assay method.**

(57) A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins complexed to the pair of nucleotide sequences.



A = TARGET POLYNUCLEOTIDE SEQUENCE

B = 1st LIGAND

C = 2nd LIGAND

D = 1st SPECIFIC NUCLEOTIDE SEQUENCE

E = 2nd SPECIFIC NUCLEOTIDE SEQUENCE

REPRESENT BONDED PAIR
OF POLYNUCLEOTIDE SEQUENCES

EP 0 453 301 A2

Jouve, 18, rue Saint-Denis, 75001 PARIS

This invention relates to methods for determining the presence of polynucleotides such as a target polynucleotide sequence in a sample and compositions and kits relating thereto.

Methods have been described for causing two nucleic acid strands to become associated as a result of the presence of a target polynucleotide. These methods are based on forming a noncovalent sandwich involving the target and two probes, each binding to a different site on the target. If the probes are contiguous or separated by one nucleotide, they can be joined in a covalent sandwich by a ligase (Goffin, C. *et al.*, *Nucleic Acids Res.* 15(21): 8755 (1987)). The ligated probe can then be amplified using known technology (Said, et al., *Science* 230:1350 (1986)). Regardless of whether the probes are ligated or amplified, provided they are covalently or non-covalently bound, the close association of the two probes can be detected by such known methods as enzyme channeling, fluorescence energy transfer and the like.

Various hybridization methods have been used in order to detect nucleic acid sequences. European Patent Application No. 0,192,168 describes a solution phase dual hybridization assay for the detection of polynucleotide sequences. The method described uses a separation probe which carries a reactive site capable of forming a stable covalent or non-covalent bond with a reaction partner. In the preferred practice of the invention, the reaction partner is attached to a solid support by covalent or non-covalent bonds.

World Patent Application No. 87/03622 describes a hybridization assay which results in high levels of amplification. Amplification is achieved by taking a primary probe, a small segment of which is hybridized to the target DNA of interest and introducing a second probe which recognizes a separate segment of the target. Using the dual probe system, increased amplification occurs upon the hybridization event taking place.

United States Patent No. 4,775,619 describes a method for the detection of a specific sequence using a hybridization technique such that duplexing of the sample DNA and a probe affects the ability to modify the spatial relationship between a label and a support. The presence of the specific sequence, the target polynucleotide, is determined by the amount of label released into the medium.

United States Patent No. 4,766,062 describes a method for determining the presence of a target polynucleotide in a sample wherein the probe polynucleotide complex is capable of base pair binding such that the target polynucleotide binds to the probe with a displacement of the labeled polynucleotide from the complex. In order for the detection system to be successful there must be sufficient base-pair binding to the target system in order to generate the release of a detectable signal.

Yet another method for the detection of nucleic acid hybridization is described in United States Patent No. 4,724,202. The patent describes a method of detection in which the known sample or separation probe is immobilized on a solid support and contacted with a mixture containing the unknown and a labeled detection probe. The labeled detection probe is created without the use of radioactivity and without chemical modification by having a single-stranded portion of nucleic acid capable of hybridizing with the unknown connected with a non-hybridizable single or double stranded nucleic acid portion. The non-hybridizable portion includes a recognition site for a particular protein.

A method for detecting the presence of a target nucleotide sequence in a polynucleotide which comprises hybridizing a first nucleotide sequence and a second nucleotide sequence to non-contiguous portions of a target nucleotide sequence and detecting the presence of such first and second nucleotide sequences is set forth in European Patent Publication No. 357,336 (corresponding to Canadian Patent Application No. 609,373 and Japanese Patent Application No. 01-218448).

None of the cited background art, however, provide a solution to the problem of detection of nucleic acids as described by the present invention. Using the methods of the present invention, a target polynucleotide sequence can be detected using the solution phase hybridization protocol which may be easily adapted to large scale immunochemical analysis. The methods described in the present invention can be easily applied to the design of diagnostic test systems.

One embodiment of the invention is a method for detecting a target polynucleotide sequence which method comprises: (a) forming in response to a target polynucleotide sequence a covalently or noncovalently bonded pair of nucleotide sequences for a portion of each of which exist a nucleotide sequence specific binding protein (NSSBP); and (b) detecting the NSSBPs complexed to the bonded pair of nucleotide sequences.

Another embodiment of the invention describes a method for detecting a target polynucleotide sequence in a medium suspected of containing the target polynucleotide sequence. The method comprises: (a) hybridizing to the 3' end of the target polynucleotide sequence a first ligand bound to the 3' end of a first specific nucleotide sequence wherein the specific nucleotide sequence is single stranded; (b) extending the target polynucleotide sequence by means of a template dependent polynucleotide polymerase and nucleoside triphosphates along the single stranded first specific nucleotide sequence thereby forming a double stranded first specific nucleotide sequence; (c) combining with the double stranded first specific nucleotide sequence, if not already combined, a second ligand bound to a second specific nucleotide sequence, and NSSBPs capable of binding the double stranded first and second specific nucleotide sequences; and (d) detecting the complex

of the NSSBPs with a bound pair of double stranded first and second specific nucleotide sequences.

In another embodiment of the invention a method for detecting a target polynucleotide sequence in a sample is described which comprises: (a) providing in combination in a liquid medium a first ligand having a sequence hybridizable with a first portion of the target polynucleotide sequence and bound to a first specific nucleotide sequence, and a second ligand having a sequence hybridizable with a second portion of the target sequence and bound to a second specific nucleotide sequence; (b) providing means for linking the first and second ligands as a function of the presence of the target sequence; (c) combining with the linked first and second ligands, first and second NSSBPs capable of binding respectively to the first and second specific binding sequences; and (d) detecting binding between the linked NSSBPs, the detection thereof indicating the presence of the target polynucleotide sequence in the sample.

In another embodiment of the invention is described a method for detecting a bonded pair of polynucleotide sequences comprising the detection of simultaneous binding of NSSBPs to two specific nucleotide sequences that comprise separate portions of the bonded pair of polynucleotide sequences.

In still another embodiment of the invention a method for performing an assay for a bonded pair of polynucleotide sequences comprised of first and second specific nucleotide sequences in a sample suspected of containing the bonded pair is described. The method comprises: (a) combining in a liquid medium (1) the sample, (2) first and second NSSBPs capable of binding, respectively, to the first and second specific nucleotide sequences wherein the first NSSBP is bound or capable of binding to a surface and the second NSSBP is bound to or capable of binding to a detectable label, and (3) the surface; (b) separating the medium from the surface; (c) combining the surface with a detectable label capable of binding the second NSSBP, when the second NSSBP is not already bound to a label; and (d) detecting the label bound to the surface.

Another embodiment of the invention describes a composition comprising a target polynucleotide bound to specific nucleotide sequences each bound to its respective NSSBP wherein one of the NSSBPs is bound to or is capable of binding to a surface and the other NSSBP is bound to or is capable of binding to a label.

In another embodiment of the invention is described a kit for use in determining a target nucleotide sequence which comprises in packaged combination (1) a pair of nucleotide sequences for a portion of each of which exists a different NSSBP, and (2) the different nucleotide specific binding proteins.

Embodiments of the invention are described below by way of example only and with reference to the accompanying drawings which show:

Figure 1: Detection of a target polynucleotide sequence by hybridization of the target polynucleotide sequence with a pre-formed double stranded 1st and 2nd specific nucleotide sequence.

Figure 2: Detection of a target polynucleotide sequence by covalent attachment, either chemical or enzymatic, of a 1st and 2nd specific nucleotide sequence to the target polynucleotide sequence.

Figure 3: Detection of a target nucleotide sequence by extension down one side of a 1st specific polynucleotide sequence.

Figure 4: Schematic of embodiment of the invention as more fully described in Example 1.

Figure 5: Schematic of embodiment of the invention as more fully described in Example 2.

Definitions

As set forth below, and for convenience in describing this invention, the following terms are defined as follows:

"Target polynucleotide sequences" shall mean all or a portion of a sequence of nucleotides to be identified, the identity of which is known to a sufficient extent so as to allow the preparation of a binding polynucleotide sequence that is complementary to and will hybridize with such target polynucleotide sequence. The target polynucleotide sequence usually will contain from about 12 to 1000 or more nucleotides, preferably 15 to 50 nucleotides. The target polynucleotide sequence may or may not be a portion of a larger molecule.

"Bonded pair of polynucleotide sequences" shall mean a first and a second polynucleotide sequence which become bonded together as a result of the presence of the target polynucleotide sequence. The bonding of the first and second polynucleotide sequences to form the bonded pair can be covalent or non-covalent.

"First ligand" shall mean a portion of a first polynucleotide sequence that is capable of hybridizing with the target nucleotide sequence by virtue of having a polynucleotide sequence complementary to a region of the target nucleotide sequence such that the first ligand will become bound to such region of the target nucleotide.

"Second ligand" shall mean a portion of a second polynucleotide sequence that is capable of hybridizing with the target nucleotide sequence at a region other than that of the first ligand.

"Ligation" shall mean the covalent attachment between the first and second nucleotide sequence. The chemical bonds are formed when the sequences are bound to the target polynucleotide sequence. Covalent

and is composed of a first ligand that is bound to the 3' end of the first specific nucleotide sequence and is capable of hybridizing with the 3' end of the target polynucleotide sequence. After causing at least the first polynucleotide sequence to hybridize with the target sequence, polynucleotide dependant nucleotide polymerase and nucleoside triphosphates are added to cause chain extension of the target sequence along the first polynucleotide sequence to form a double stranded specific nucleotide sequence. The second polynucleotide sequence is then caused to hybridize with the target sequence, if not carried out previously, thereby forming a bonded pair of polynucleotide sequences. NSSBPs capable of specifically binding the specific nucleotide sequences in the bonded pair are then added and detection of simultaneous binding to the bonded pair is carried out as described above.

Generally, a combination is provided in a liquid medium comprising a sample suspected of containing a target polynucleotide sequence, a first polynucleotide sequence complementary to a first portion of the target polynucleotide sequence, a second polynucleotide sequence complementary to a portion of the target polynucleotide sequence other than the first portion and means for hybridizing the first and second sequences with the target polynucleotide sequence.

The order of combining of the various reagents to form the combination may vary and can be simultaneous or wholly or partially sequential. Generally, a sample containing a target polynucleotide sequence is obtained. This may be combined with a pre-prepared combination of first and second nucleotide sequences, nucleoside triphosphates, and polynucleotide polymerase. Following these additions a ligase or other means to produce ligation can optionally be employed. Simultaneous addition of the above, as well as other step-wise or sequential orders of addition, may be employed. The concentration and order of addition of reagents and conditions for the method are governed generally by the desire to optimize hybridization of all the first and second nucleotide sequences with the target nucleotide sequence.

In carrying out the method of the invention an aqueous medium will be employed. The pH for the medium will usually be in the range of about 4.5 to 9.5, more usually in the range of about 5.5-8.5, and preferably in the range of about 6-8. The pH and temperature are chosen and varied, as the case may be, so as to provide for either simultaneous or sequential hybridization of the target sequence with the first and second polynucleotide sequences or extension of the first and second polynucleotide sequence along the target polynucleotide sequence. Various buffers may be used to achieve the desired pH and maintain the pH during the determination. Illustrative buffers include borate, phosphate, carbonate, Tris, barbitol and the like. The particular buffer employed is not critical to this invention but in individual methods one buffer may be preferred over another.

Moderate temperatures are normally employed for carrying out the method and desirably constant temperatures during the period for conducting the method. The temperatures for the method will generally range from about 20 to 90°C, more usually from about 30 to 70°C preferably 37 to 50°C. However, the temperature can be varied depending on whether the above steps are carried out sequentially or simultaneously. For example, relatively low temperatures of from about 20 to 40°C can be employed for the chain extension step, while denaturation and hybridization can be carried out at a temperature of from about 40 to 80°C.

The time period for carrying out the method of the invention will generally be long enough to achieve attachment between the first and second polynucleotide sequences, when these sequences are attached to the target polynucleotide sequence and determining whether such attachment has occurred. Generally, the time period for conducting the method will be from about 5 to 200 min. As a matter of convenience, it will usually be desirable to minimize the time period.

The concentration of the target polynucleotide sequence to be determined can be as low as 10^{-21} M in a sample but will generally vary from about 10^{-14} M to 10^{-19} M, more usually from about 10^{-15} to 10^{-18} M. The concentration of the first and second polynucleotide sequence and the deoxynucleoside triphosphates in the medium can vary widely. Preferably, these reagents will be present in large molar excess over the amount of target polynucleotide sequence expected. The deoxynucleoside triphosphates will usually be present in 10^{-6} to 10^{-2} M, preferably 10^{-6} to 10^{-3} M. The second polynucleotide sequences, as well as the first polynucleotide sequence, will usually be present in at least 10^{-12} M, preferably 10^{-10} M, more preferably at least about 10^{-9} M.

The concentration of the polymerase and any cofactors in the medium can also vary substantially. These reagents may be present in as low as 10^{-12} M but may be present in a concentration at least as high or higher than the concentration of the first and second polynucleotide sequences, the primary limiting factor being the cost of the reagents, which are usually enzymes. The final concentration of each of the reagents will normally be determined empirically to optimize the present method with respect to both speed and sensitivity.

When used together with target mediated ligation and single primer amplification, the methods of the present invention provide a homogeneous DNA assay procedure. In general, the assay procedure consists of mixing together sample containing the target nucleotide sequence under conditions which cause complexation of the probes with the target. A ligase is added to cause linking of probes to bound target. Nucleoside triphosphates are added together with a primer containing the complementary sequence at its 3' end and a nucleotide

polymerase. Conditions are provided to cause amplification of the ligated sequence, which comprises the first ligand and second ligand bonded at their 5' and 3' ends, respectively. (See, for example, EP Publication No. 357,338, referenced above.)

In one application of the present invention, protein receptors capable of binding to the first ligand and the second ligand, usually when complexed with a complementary sequence, are combined where the first and second ligands are labeled according to any of the above methods that allow homogeneous detection, e.g., fluorescent beads and carbon particles, enzymes that can channel, and the like.

The signal associated with binding to the first and second specific nucleotide sequence is detected without separation from the assay medium. Detection of the signal will depend upon the nature of the signal producing system utilized. For example, the label may be selected from a group consisting of an enzyme, catalyst, fluorophore, chemiluminescer, electroactive reporter group, light absorbant dye, metal cluster, a 20-1000 nm particle or a nucleic acid sequence.

If the label or reporter group is an enzyme, additional members of the signal producing system would include enzyme substrates and so forth. The product of the enzyme reaction is preferably a dye that can be detected spectrophotometrically. If the label is a fluorescent molecule the medium can be irradiated and the fluorescence determined. Where the label is a radioactive group, the medium can be counted to determine the radioactive count. The label may also be detected by electromagnetic radiation.

Another aspect of the invention provides for a composition comprising a target polynucleotide bound to specific nucleotide sequences each bound to its respective nucleotide sequence specific binding protein (NSSBP) wherein one of the NSSBP is bound to or is capable of binding to a surface and the other NSSBP is bound to or is capable of binding to a label. In such a composition, the specific nucleotide sequences may be covalently bound to each other; also, preferably, the specific nucleotide sequences are double stranded. Appropriate labels for such compositions are as defined above.

The reagents employed in the present invention can be provided in a kit in packaged combination with predetermined amounts of reagents for use in the present method in assaying for a target polynucleotide sequence present in a sample. For example, a kit useful in the present method can comprise in packaged combination with other reagents, first and second polynucleotide sequences and the corresponding nucleotide sequence specific binding proteins. The kit can further include in the packaged combination nucleoside triphosphates such as deoxynucleoside triphosphates, e.g., deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP), and corresponding derivatives thereof. The kit can further include a polynucleotide polymerase and also means for covalently attaching the first and second sequences, such as a ligase.

The relative amounts of the various reagents in the kits can be varied widely to provide for concentrations of the reagents which substantially optimize the reactions that need to occur during the present method and to further substantially optimize the sensitivity of the assay. Under appropriate circumstances one or more of the reagents in the kit can be provided as a dry powder, usually lyophilized, including excipients, which on dissolution will provide for a reagent solution having the appropriate concentrations for performing a method or assay in accordance with the present invention. Each reagent can be packaged in separate containers or some reagents can be combined in one container where reactivity and shelf life will permit.

The assay described in the present invention can be used to detect specific target polynucleotide sequences comprising a portion of the sample of interest. The sample of interest may be used directly where the target polynucleotide is single stranded or may be treated to denature double stranded target sequences and optionally cleave the target to obtain a fragment that contains a target polynucleotide sequence. The sample can be cleaved by known techniques such as treatment with a restriction endonuclease or other site specific chemical or enzymatic cleavage methods.

The target polynucleotide sequence may comprise a portion of, for example, nucleic acids from any source in purified or unpurified form including DNA (dsDNA and ssDNA) and RNA, including t-RNA, m-RNA, r-RNA, mitochondrial DNA and RNA, chloroplast DNA and RNA, DNA-RNA hybrids, or mixtures thereof, genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and fragments thereof, and the like. The target polynucleotide sequence can be only a minor fraction of a complex mixture such as a biological sample. The target polynucleotide sequence can be obtained from various biological material by procedures well known in the art. Some examples of such biological material by way of illustration and not limitation are disclosed in Table I below.

Table I

Microorganisms of interest include:

5	<u>Corynebacteria</u> Corynebacterium diphtheria <u>Pneumococci</u> Diplococcus pneumoniae <u>Streptococci</u> Streptococcus pyrogenes	
10	Streptococcus salivarius <u>Staphylococci</u> Staphylococcus aureus Staphylococcus albus <u>Neisseriae</u> Neisseria meningitidis	
15	Neisseria gonorrhea <u>Enterobacteriaceae</u> Escherichia coli Aerobacter aerogenes	The coliform bacteria
20	Klebsiella pneumoniae Salmonella typhosa Salmonella choleraesuis Salmonella typhimurium Shigellae dysenteriae Shigellae schmitzii Shigellae arabinotarda	The Salmonellae The Shigellae
25	Shigellae flexneri Shigellae boydii Shigellae sonnei <u>Other enteric bacilli</u> Proteus vulgaris Proteus mirabilis	 Proteus species
30	Proteus morgani Pseudomonas aeruginosa Alcaligenes faecalis Vibrio cholerae <u>Hemophilus-Bordetella group</u> Hemophilus influenza, H. ducryi	
35	Hemophilus hemophilus Hemophilus aegypticus Hemophilus parainfluenzae Bordetella pertussis Phycomycetes <u>Pasteurellae</u> Pasteurella pestis Pasteurella tularensis	Rhizopus oryzae Rhizopus arrhizus Rhizopus nigricans Sporotrichum schenckii Fonsecaea pedrosi Fonsecaea compact Fonsecaea dermatidis Cladosporium carrioni Phialophora verrucosa Aspergillus nidulans Madurella mycetomi Madurella grisea Allancharia boydii
40	<u>Brucellae</u> Brucella melitensis Brucella abortus Brucella suis	

45

50

55

	<u>Aerobic Spore-forming Bacilli</u>	<u>Phialophora jeanselmei</u>
	<u>Bacillus anthracis</u>	<u>Microsporum gypsum</u>
	<u>Bacillus subtilis</u>	<u>Trichophyton mentagrophytes</u>
	<u>Bacillus megaterium</u>	<u>Keratinomyces ajelloi</u>
	<u>Bacillus cereus</u>	<u>Microsporum canis</u>
5	<u>Anaerobic Spore-forming Bacilli</u>	<u>Trichophyton rubrum</u>
	<u>Clostridium botulinum</u>	<u>Microsporum adouini</u>
	<u>Clostridium tetani</u>	<u>Viruses</u>
	<u>Clostridium perfringens</u>	<u>Adenoviruses</u>
	<u>Clostridium novyi</u>	<u>Herpes Viruses</u>
	<u>Clostridium septicum</u>	<u>Herpes simplex</u>
10	<u>Clostridium histolyticum</u>	<u>Varicella (Chicken pox)</u>
	<u>Clostridium tertium</u>	<u>Herpes Zoster (Shingles)</u>
	<u>Clostridium bifermentans</u>	<u>Virus B</u>
	<u>Clostridium sporogenes</u>	<u>Cytomegalovirus</u>
	<u>Mycobacteria</u>	<u>Rex Viruses</u>
15	<u>Mycobacterium tuberculosis hominis</u>	<u>Variola (smallpox)</u>
	<u>Mycobacterium bovis</u>	<u>Vaccinia</u>
	<u>Mycobacterium avium</u>	<u>Poxvirus bovis</u>
	<u>Mycobacterium leprae</u>	<u>Paravaccinia</u>
	<u>Mycobacterium paratuberculosis</u>	<u>Molluscum contagiosum</u>
	<u>Actinomyces</u> (fungus-like bacteria)	<u>Picornaviruses</u>
	<u>Actinomyces israeli</u>	<u>Poliovirus</u>
20	<u>Actinomyces bovis</u>	<u>Coxsackievirus</u>
	<u>Actinomyces naeslundii</u>	<u>Echoviruses</u>
	<u>Nocardia asteroides</u>	<u>Rhinoviruses</u>
	<u>Nocardia brasiliensis</u>	<u>Myxoviruses</u>
	<u>The Spirochetes</u>	<u>Influenza (A, B, and C)</u>
	<u>Treponema pallidum</u>	<u>Parainfluenza (1-4)</u>
25	<u>Treponema pertense</u>	<u>Mumps Virus</u>
	<u>Spirillum minus</u>	
	<u>Streptobacillus moniliformis</u>	<u>Newcastle Disease Virus</u>
	<u>Treponema carateum</u>	<u>Measles Virus</u>
	<u>Borrelia recurrentis</u>	<u>Rinderpest Virus</u>
	<u>Leptospira icterohemorrhagiae</u>	<u>Canine Distemper Virus</u>
30	<u>Leptospira canicola</u>	<u>Respiratory Syncytial Virus</u>
	<u>Trypanosomes</u>	<u>Rubella Virus</u>
	<u>Mycoplasmas</u>	<u>Arboviruses</u>
	<u>Mycoplasma pneumoniae</u>	
	<u>Other pathogens</u>	
35	<u>Eastern Equine Encephalitis Virus</u>	
	<u>Listeria monocytogenes</u>	
	<u>Western Equine Encephalitis Virus</u>	
	<u>Erysipelothrix rhusiopathiae</u>	
	<u>Sindbis Virus</u>	
	<u>Streptobacillus moniliformis</u>	
40	<u>Chikungunya Virus</u>	
	<u>Donovania granulomatis</u>	
	<u>Semliki Forest Virus</u>	
	<u>Bartonella bacilliformis</u>	
	<u>Mayora Virus</u>	
45		
50		
55		

5 Rickettsiae (bacteria-like parasites)
 St. Louis Encephalitis Virus
 Rickettsia prowazekii
 California Encephalitis Virus
 Rickettsia mooseri
 Colorado Tick Fever Virus
 Rickettsia rickettsii
 Yellow Fever Virus
 Rickettsia conorii
 10 Dengue Virus
 Rickettsia australis
Reoviruses
 Rickettsia sibiricus
 Reovirus Types 1-3
 Rickettsia akari
 15 Human Immunodeficiency Viruses (HIV)
 Rickettsia tsutsugamushi
 Human T-cell Lymphotropic
 Virus I & II (HTLV)
 Rickettsia burnetii
 Rickettsia quintana
 20 Retroviruses
Hepatitis
 Hepatitis A Virus
 Hepatitis B Virus
 Hepatitis nonA-nonB Virus
 Chlamydia (unclassifiable parasites
 bacterial/viral)
 25 Chlamydia agents (naming uncertain)
Tumor Viruses
Fungi
 Rauscher Leukemia Virus
 Cryptococcus neoformans
 Gross Virus
 30 Blastomyces dermatidis
 Maloney Leukemia Virus
 Histoplasma capsulatum
 Coccidioides immitis
 Human Papilloma Viruses
 Paracoccidioides brasiliensis
 35 Candida albicans
 Aspergillus fumigatus
 Mucor corymbifer (Absidia corymbifera)

40 The double receptor polynucleotide assay method as described by invention provides a simple and straight
 forward assay method easily adaptable to a diagnostic testing system. The specific target nucleotide sequence
 identified using this assay method will frequently be characteristic of a particular disease state, genetic charac-
 teristic or abnormality.

45 EXAMPLES

The following examples are illustrative, and not limiting of the invention. General conditions for nucleic acid
 hybridization and the use of DNA and RNA modifying enzymes can be found in Molecular Cloning: A Laboratory
Manual by Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Laboratory Press (1989).

50 Unless otherwise described, the following materials and methods for production of necessary reagents of
 use in carrying out the invention are known in the art and can be obtained as follows:

The lactose repressor protein may be prepared as described in the literature:

Rosenberg, J.M. et al. Nucleic Acid Res. 4(3):567 (1977)

Matthews, K.S., J. Biol. Chem. 253(12):4279 (1978)

O'Gorman, R.B. et al. J. Biol. Chem. 255(21):10100 (1980)

55 Levens, D. and P.M. Howley, Mol. Cell. Biol. 5(9):2307 (1985)

The presence, activity and degree of purity of the lactose repressor protein prepared using the above refer-
 enced methods can be determined using procedures described in the literature. In particular, Bourgeois, S. and
 A.D. Riggs, Biochem. Biophys. Res. Comm. 38(2):348 (1970); Barkley, M.D. and S. Bourgeois in The Operon,

Cold Spring Harbor, N.Y. pp.177-220 (1978); and Bourgeois, S. In Methods in Enzymology Vol. 21, pp.491-500 (1971).

The tetracycline (tet) repressor protein may be prepared as described in the literature:

Hillen, W., et al. J. Mol. Biol. 257(11):6805 (1982)

Oehmichen, R. et al. EMBO J. 3(3):539 (1984)

The tet repressor protein may be assayed and characterized as described by:

Aittschemled, L. and W. Hillen, J. Mol. Biol. 187:341 (1986)

Hillen, W. et al. J. Mol. Biol. 172:185 (1984)

Hillen, W. et al. J. Mol. Biol. 169:707 (1983)

EXAMPLE 1:

The presence or absence of the target DNA in a sample is determined by adding an aliquot of sample to a convenient volume of hybridization buffer, for example, 10 mM Tris (pH 7.5), 1 mM EDTA. The hybridization buffer will also contain approximately 1 mM of the first and second ligand containing nucleic acid sequences such as are shown in Figures 1 and 2. In one application of the example the nucleotide sequence of the D and E regions (see Figures 1 and 2) are those of lactose (lac) operator and tetracycline (tet) operator respectively as known from and described in the literature cited above. After denaturing any target DNA present into single strands by heating to approximately 98°C for at least 2 minutes, the temperature of the solution is reduced so as to allow hybridization of the ligand sequence to any target nucleic acid present in the sample. The exact hybridization temperature may be calculated from the cited references considering the length of the ligand sequences to be hybridized to the target and the %AT base composition. The reaction time necessary for substantially complete hybridization will also typically be calculated from equations well known in the literature and again depending on the length of the ligand sequence and its complexity (see, for example, Albrechtsen, C. et al. Anal. Biochem. 170:193 (1988), Matthews, J.A. and Kricka, L.J. Anal. Biochem. 169:1 (1988), Melnikoth, J. and Wahl, G. Anal. Biochem. 138:267 (1984), and Miyada, C.G. and Wallace, R.B. Methods in Enzymology, 154:94 (1987)).

Following the formation of the ternary complex (comprising the target polynucleotide sequence A, the nucleotide sequences of the D and E regions, and the first and second ligand, B and C, as is shown in Figures 1 and 2), the solution is cooled to room temperature and a beta-galactosidase-lac repressor fusion protein (Promega Corp., Madison, WI), and anti-beta-galactosidase mouse monoclonal antibody (Promega Corp., Madison, WI), and a solid surface (such as a bead) immobilized rabbit-anti-mouse antibody (RAM bead, Bio-Rad Laboratories, Richmond CA) are added to the mixture. The concentration of these components and incubation time (approximately 15 minutes) will be such that all the lac operator containing nucleic acid sequence is bound onto the solid surface. The solid surface is separated from the liquid phase by centrifugation. After a washing step (an equal volume of 10 mM Tris, pH=7.5, 100 mM NaCl) and centrifugation, labeled tet repressor protein is added the tet repressor binding conditions described in the literature and referenced above. Following incubation (typically 15 minutes), removal of the unbound protein, and washing, the amount of labeled repressor material remaining above that observed with the negative control (i.e. lacking any sample or target nucleic acid) is a measure of the presence and amount of target nucleic acid present in the sample.

The second repressor in this example may be labeled by modification with a fluorescent dye, a radioactive marker (such as 125-Iodine), or by means of a covalently attached enzyme label turning over a detectable product when provided with its appropriate substrates in the final step of the detection reaction. The final configuration of this assay is shown with a model duplex DNA in Figure 4.

EXAMPLE 2:

An alternative method of carrying out the present invention is schematically set forth in Figure 5. In this example, the tetracycline repressor protein is immobilized on a solid surface. This may be accomplished by passive adsorption or by the use of a covalent bond. For examples of methods for the immobilization of proteins see Affinity Chromatography: a Practical Approach, Dean, P.D.G. et al. eds., IRL Press, (1985), in particular, chapter 5 and the references contained therein.

In the example outlined in Figure 5, the ternary complex produced as in Example 1 is added to the immobilized binding protein. After a suitable incubation time to allow binding (typically 15 minutes) and a washing step to remove unbound material, a second DNA binding protein, for example, the beta-galactosidase-lac repressor fusion protein is added. The second DNA binding protein is allowed to bind and washed so as to remove unbound and non-specifically bound beta-galactosidase activity. A substrate for beta-galactosidase is then

added (for example "Blue-gal", pNPG, or X-gal; BRL, Gaithersburg, MD), and the presence of the target nucleic acid is inferred from the formation of colored dye.

The above description and examples fully disclose the invention including preferred embodiments thereof. Modifications of the methods described that are obvious to those of ordinary skill in molecular biology and related sciences are intended to be within the scope of the following claims.

Claims

- 10 1. A method for detecting a target polynucleotide sequence which method comprises:
 - a) forming in response to a target polynucleotide sequence a covalently or noncovalently bonded pair of nucleotide sequences for a portion of each of which exists a nucleotide sequence specific binding protein (NSSBP); and
 - b) detecting the NSSBPs complexed to the bonded pair of nucleotide sequences.
- 15 2. The method of claim 1 for detecting a target polynucleotide sequence wherein the bonding between the pair of nucleotide sequences is covalent.
3. The method of claim 2 wherein the pair of nucleotide sequences are bonded to two non-contiguous portions of the target polynucleotide sequence.
- 20 4. The method of claim 1 wherein the bonded pair of nucleotide sequences comprise (a) a first ligand having a sequence hybridizable with a first portion of the target polynucleotide sequence; (b) a second ligand having a sequence hybridizable with a second portion of the target polynucleotide sequence other than the first portion; and (c) a specific nucleotide sequence ligated to the first ligand and a specific nucleotide sequence ligated to the second ligand.
- 25 5. The method of claim 4 wherein the first and second ligands are rendered covalently bindable to each other in response to the presence of a target molecule.
- 30 6. The method of claim 4 wherein the first and second ligands are attached to different specific nucleotide sequences, each sequence capable of binding a NSSBP selected from the group consisting of repressors, activators, restriction endonucleases, polypeptide fragments and RNA polymerases.
- 35 7. The method of claim 1 for detecting a target polynucleotide sequence wherein the bonded pair of nucleotide sequences is formed by ligation of a first and a second ligand hybridized to portions of the target polynucleotide sequence separated by at least a single nucleotide.
- 40 8. A method for detecting a target polynucleotide sequence in a medium suspected of containing a target polynucleotide sequence comprising:
 - a) hybridizing to the 3' end of the target polynucleotide sequence a first ligand bound to the 3' end of a first specific nucleotide sequence wherein the specific nucleotide sequence is single stranded;
 - b) extending the target polynucleotide sequence by means of a template dependent polynucleotide polymerase and nucleoside triphosphates along the single stranded first specific nucleotide sequence thereby forming a double stranded first specific nucleotide sequence;
 - 45 c) combining with the double stranded first specific nucleotide sequence having the first specific nucleotide sequence, if not already combined, a second ligand bound to a second specific nucleotide sequence, and nucleoside sequence specific binding proteins (NSSBPs) capable of binding the double stranded first and second specific nucleotide sequences; and
 - 50 d) detecting the complex of the NSSBPs with a bound pair of double stranded first and second specific nucleotide sequence.
9. A composition comprising a target polynucleotide bound to specific nucleotide sequences each bound to its respective nucleotide sequence specific binding protein (NSSBP) wherein one of the NSSBP is bound to or is capable of binding to a surface and the other NSSBP is bound to or is capable of binding to a label.
- 55 10. A kit for use in determining a target nucleotide sequence which comprises in packaged combination:
 - a pair of nucleotide sequences for a portion of each of which exists a different nucleotide sequence

specific binding protein (NSSBP), and
the different nucleotide sequence specific binding proteins.

6

10

16

20

26

30


36

40

46

50

56



A = TARGET POLYNUCLEOTIDE SEQUENCE


B = 1st LIGAND

C = 2nd LIGAND

D = 1st SPECIFIC NUCLEOTIDE SEQUENCE

E = 2nd SPECIFIC NUCLEOTIDE SEQUENCE

REPRESENT BONDED PAIR
OF POLYNUCLEOTIDE SEQUENCES



A = TARGET POLYNUCLEOTIDE SEQUENCE

B = 1st LIGAND

C = 2nd LIGAND


D = 1st SPECIFIC NUCLEOTIDE SEQUENCE

E = 2nd SPECIFIC NUCLEOTIDE SEQUENCE

F = COVALENT BOND OR BRIDGE

REPRESENT BONDED PAIR
OF POLYNUCLEOTIDE SEQUENCES

Fig. 3.




A = TARGET POLYNUCLEOTIDE SEQUENCE
 B = 1st SPECIFIC POLYNUCLEOTIDE SEQUENCE
 C = 2nd SPECIFIC POLYNUCLEOTIDE SEQUENCE
 D = 2nd LIGAND

TDPNP = TEMPLATE-DEPENDENT POLYNUCLEOTIDE POLYMERASE
 d x TP's = NUCLEOSIDE TRIPHOSPHATES


** = BLOCKED SO AS TO DISALLOW EXTENSION

Fig. 4.



A = RABBIT ANTI-MOUSE ANTIBODY
 B = ANTI β -GALACTOSIDASE ANTIBODY
 C = β -GALACTOSIDASE - lac REPRESSOR FUSION PROTEIN
 D = TARGET NUCLEOTIDE SEQUENCE
tet = Tet REPRESSOR PROTEIN DIMER
tet_R = Tet OPERATOR DNA SEQUENCE

Fig. 5.



I.-IV. = ALTERNATE METHODS OF BINDING tet REPRESSOR PROTEIN TO MICROTITER WELLS

O = tet REPRESSOR PROTEIN DIMER

~~~~~ = COVALENTLY ATTACHED tet REPRESSOR PROTEIN

O-B = tet REPRESSOR PROTEIN BOUND TO BIOTIN

A = AVIDIN

O~~~~H = tet REPRESSOR PROTEIN BOUND TO HAPTEN

Y = IMMOBILIZED ANTIBODY TO HAPTEN



Publication number : **0 453 301 A3**

**EUROPEAN PATENT APPLICATION**

Application number : **91303516.8**

Int. Cl.<sup>5</sup> : **C12Q 1/68, G01N 33/50**

Date of filing : **19.04.91**

Priority : **20.04.90 US 511651**

Date of publication of application :  
**23.10.91 Bulletin 91/43**

Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

Date of deferred publication of search report :  
**21.07.93 Bulletin 93/29**


Applicant : **SYNTEX (U.S.A.) INC.**  
**3401 Hillview Avenue**  
**Palo Alto California 94304 (US)**

Inventor : **Ullman, Edwin F.**  
**135 Selby Lane**  
**Atherton, California 94025 (US)**  
Inventor : **Goodman, Thomas C.**  
**2435 Whitney Drive**  
**Mountain View, California 94043 (US)**

Representative : **Nicholls, Kathryn Margaret et al**  
**Mawburn Ellis, 2 Cursitor Street**  
**London EC4A 1BQ (GB)**

**Double receptor polynucleotide assay method.**

A method for the detection of a polynucleotide target sequence is described. The method involves the formation of a covalent or non-covalent bonded pair of nucleotide sequences formed in response to a target polynucleotide sequence, adding nucleotide sequence specific binding proteins each capable of binding one member of the pair of nucleotide sequences, and detecting the specific binding proteins complexed to the pair of nucleotide sequences.



A = TARGET POLYNUCLEOTIDE SEQUENCE  
 B = 1st LIGAND  
 C = 2nd LIGAND  
 D = 1st SPECIFIC NUCLEOTIDE SEQUENCE  
 E = 2nd SPECIFIC NUCLEOTIDE SEQUENCE

REPRESENT BONDED PAIR OF POLYNUCLEOTIDE SEQUENCES

EP 0 453 301 A3

Jouve, 18, rue Saint-Denis, 75001 PARIS





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 91 30 3516 -B

| DOCUMENTS CONSIDERED TO BE RELEVANT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                   |                                                        |                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|
| Category                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Citation of document with indication, where appropriate, of relevant passages                                                                                                                                     | Relevant to claim                                      | CLASSIFICATION OF THE APPLICATION (Int. Cl.5)        |
| D,Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | EP-A-0 192 168 (MOLECULAR DIAGNOSTICS INC.)<br>* claims 1-10; figure 1 *                                                                                                                                          | 1,9,10                                                 | C12Q1/68<br>G01N33/50                                |
| Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | WO-A-8 912 696 (AMGEN INC)<br>* claims 6-13; figure 2 *                                                                                                                                                           | 1-10                                                   |                                                      |
| Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | EP-A-0 147 665 (MOLECULAR DIAGNOSTICS INC.)<br>* the whole document *                                                                                                                                             | 1-10                                                   |                                                      |
| Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | EP-A-0 185 494 (APPLIED BIOSYSTEMS INC)<br>* the whole document *                                                                                                                                                 | 1-10                                                   |                                                      |
| Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | GB-A-2 125 964 (CETUS MADISON)<br>* the whole document *                                                                                                                                                          | 1-10                                                   |                                                      |
| D,Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | EP-A-0 357 336 (SYNTEX(U.S.A.) INC.)<br>* the whole document *                                                                                                                                                    | 1-10                                                   |                                                      |
| Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | PROC. NATL. ACAD. SCI. USA<br>vol. 86, April 1989, USA<br>pages 2423 - 2427<br>KEMP, D. ET AL. 'Colorimetric detection of specific DNA segments amplified by polymerase chain reaction'<br>* the whole document * | 1,8                                                    | TECHNICAL FIELDS<br>SEARCHED (Int. Cl.5)<br><br>C12Q |
| The present search report has been drawn up for all claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                   |                                                        |                                                      |
| Place of search<br><b>THE HAGUE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                   | Date of completion of the search<br><b>11 MAY 1993</b> | Examiner<br><b>OSBORNE H.H.</b>                      |
| <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone<br/> Y : particularly relevant if combined with another document of the same category<br/> A : technological background<br/> O : non-written disclosure<br/> P : intermediate document</p> <p>T : theory or principle underlying the invention<br/> E : earlier patent document, but published on, or after the filing date<br/> D : document cited in the application<br/> L : document cited for other reasons<br/> A : member of the same patent family, corresponding document</p> |                                                                                                                                                                                                                   |                                                        |                                                      |